98%
921
2 minutes
20
Background: The body of patients with chronic kidney disease (CKD)is in a state of microinflammation, which further aggravates the progression of CKD and the occurrence and development of its complications. The inflammatory state of the body is significantly increased in patients with secondary hyperparathyroidism of CKD.
Methods: Patients diagnosed with chronic kidney disease in the department of Nephrology of Henan Provincial People's Hospital were selected as the experimental group, and 58 normal subjects were selected as the control group. Collecting patient's Clinical date, whole blood of the experimental group and control group was collected, and hs-CRP was detected by enzyme-linked immunosorbent assay. Compare the differences in clinical indicators and serum hs-CRP between the two groups. Taking PTH and hs-CRP as dependent variables, correlation analysis was conducted to clarify the relationship between PTH and hs-CRP, and further curve fitting was carried out.
Results: The levels of hemoglobin, total protein and albumin in CKD group were significantly lower than those in control group ( < 0.001). Alkaline phosphatase, creatinine, uric acid, Cyc and blood phosphorus in CKD group were higher than those in control group, and the values were 0.016, <0.001, <0.001, <0.001, <0.001, respectively. Blood calcium was lower than control group, < 0.001. The levels of hs-CRP in CKD group were significantly higher than those in control group, < 0.001. Serum PTH was positively correlated with serum hs-CRP ( = 0.299, = 0.002) in a normalized holistic analysis of CKD patients. In order to further clarify the correlation between PTH and hs-CRP, quadratic method was used to conduct curve fitting on PTH and hs-CRP and found that = 0.361, = 7.795, < 0.001. Quadratic method was used to quadratic curve fitting at PTH levels <600 pg/mL, <500 pg/mL, <400 pg/mL, <300 pg/mL and <200 pg/mL, respectively, and it was found that the corresponding = 0.281, = 4.158, < 0.001. = 0.292, = 4.397, < 0.001; = 0.546, = 18.456, < 0.001; = 0.415, = 7.471, < 0.001; = 0.403, = 5.220, < 0.001. It was found that there was no correlation between PTH and hs-CRP in hemodialysis patients and peritoneal dialysis patients. In order to exclude the influence of drug use on the statistical results, after excluding the patients who took over phosphorus binder and calcium binder, curve fitting method was used to find that PTH and CRP were correlated, in peritoneal dialysis group and hemodialysis group, = 0.953, = 39.913, < 0.001; = 0.448, = 3.391, = 0.010 respectively.
Conclusion: CKD patients have the lowest levels of inflammatory factors within a certain range of PTH.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337739 | PMC |
http://dx.doi.org/10.1080/07853890.2025.2541080 | DOI Listing |
J Am Soc Nephrol
September 2025
AP-HP, Nephrology Department, European Georges Pompidou Hospital, Paris, France.
Nephrol Dial Transplant
September 2025
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: We investigated circulating protein profiles and molecular pathways among various chronic kidney disease (CKD) etiologies to study its underlying molecular heterogeneity.
Methods: We conducted a proteomic biomarker analysis in the DAPA-CKD trial recruiting adults with and without type 2 diabetes with an eGFR of 25 to 75 mL/min/1.73m2 and a UACR of 200 to 5000 mg/g.
Clin J Am Soc Nephrol
September 2025
Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
Oncologist
September 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
University Sousse, Faculty of Medicine "Ibn El-Jazzar", Department of Medical Genetics, Sousse, Tunisia.
The global epidemic of overweight and obesity is closely linked to the development of chronic kidney disease (CKD), with extremely obese individuals facing a particularly high risk. This study aimed to assess the relationship between lipid profile levels, SIRT1 expression, and RNA-34a-5P in the regulation of blood lipid levels among severely obese individuals with renal diseases. Conducted over six months in three specialized hospitals, the study included 100 participants divided into two groups: 50 obese individuals with renal diseases and 50 obese controls without renal problems.
View Article and Find Full Text PDF